About Nuvalent
Nuvalent is a company based in Cambridge (United States) founded in 2017 was acquired by GSK in June 2026. Nuvalent has raised $185 million across 2 funding rounds from investors including Fidelity Investments, Janus Henderson Investors and Driehaus. The company has 142 employees as of December 31, 2024. Nuvalent offers products and services including Zidesamtinib, Neladalkib, and NVL-330. Nuvalent operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Cambridge, United States
- Employees 142 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nuvalent, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$260.76 M (USD)-106.59as on Dec 31, 2024
-
EBITDA
-$280.37 M (USD)-87.55as on Dec 31, 2024
-
Total Equity Funding
$185 M (USD)
in 2 rounds
-
Latest Funding Round
$135 M (USD), Series B
May 11, 2021
-
Investors
Fidelity Investments
& 12 more
-
Employee Count
142
as on Dec 31, 2024
-
Acquired by
GSK
(Jun 09, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Nuvalent
Nuvalent is a publicly listed company on the NASDAQ with ticker symbol NUVL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Nuvalent
Nuvalent offers a comprehensive portfolio of products and services, including Zidesamtinib, Neladalkib, and NVL-330.
Targets advanced ROS1-positive NSCLC in clinical trials.
Inhibits ALK-positive NSCLC for patient treatment.
Focuses on HER2-altered NSCLC in phase 1 studies.
People of Nuvalent
Unlock access to complete
Unlock access to complete
Leadership Team
29 people
Software Development Team
7 people
Scientific Team
5 people
Human Resources and Administration
5 people
Product Management Team
4 people
Finance and Accounting
4 people
Senior Team
3 people
Data Analysis and Operations Team
3 people
Unlock access to complete
Funding Insights of Nuvalent
Nuvalent has successfully raised a total of $185M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $135 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nuvalent
Nuvalent has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Janus Henderson Investors and Driehaus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Private investment firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Venture capital fund focused on biotechnology startups
|
Locked | Locked | Locked |
Investor details for Nuvalent
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nuvalent
Investment portfolio details for Nuvalent
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Nuvalent
Detailed financials for Nuvalent
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nuvalent Comparisons
Peer comparison for Nuvalent
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nuvalent
Nuvalent operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
Detailed competitors of Nuvalent
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nuvalent
Complete news archive for Nuvalent
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nuvalent
Nuvalent was founded in 2017 and raised its 1st funding round 4 years after it was founded.
Nuvalent is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
James Porter is the current CEO of Nuvalent.
Nuvalent is a funded company, having raised a total of $185M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Nuvalent is 142.
Nuvalent was founded in 2017 and is based in Cambridge, United States. Oncology therapeutics are developed by the company, with emphasis on ROS1-selective inhibitors for non-small cell lung cancer and central nervous system metastasis. Drug candidates such as NUV-520 and NUV-655 are advanced to address lung cancer, breast cancer, and additional tumor types in clinical settings.
Nuvalent's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Nuvalent offers Zidesamtinib, Neladalkib, and NVL-330.
Yes, Nuvalent is publicly traded on NASDAQ under the ticker symbol NUVL.
Nuvalent has 13 investors. Key investors include Fidelity Investments, Janus Henderson Investors, Driehaus, GSK, and Deerfield.
The ticker symbol of Nuvalent is NUVL on NASDAQ.